Robert Allen Burger, M.D., FACOG, FACS

faculty photo
Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
University of Pennsylvania
3400 Civic Center Blvd.
South Tower 10-173
Philadelphia, PA 19104-5156
Office: 215-220-9513
Fax: 215-220-9515
Education:
A.B. (Biochemistry)
Harvard University, Cambridge, MA, 1984.
M.D.
New York University, New York, NY, 1988.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ: Nomogram Predicting Individual Survival Following Recurrence in Advanced Stage High Grade Ovarian Cancer from NRG/GOG Randomized Trials of Platinum and Paclitaxel. Obstetrics & Gynecology In Press, 2019.

Arend RC, Toboni M, Montgomery AM, Burger RA, Olawaiye AB, Monk BJ, Herzog T.: Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. The Oncologist 12: 1533-1545, Dec 2018.

Burger RA; Sill M; Zamarin D; Powell D; Frak I; Zivanovic O; Gunderson C; Ko E; Mathews C; Sharma S; Hagemann A; Khleif S; Aghajanian C: NRG Oncology Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Ovarian Cancer. Late breaking abstract oral presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) Sep 2018.

Nasioudis D; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Ko EM; Latif NA.: Type of treatment facility impacts survival of patients with ovarian clear cell carcinoma. Poster presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) Sep 2018.

Nasioudis D; Kanninen T; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Ko EM; Latif NA.: Residual disease is associated with a worse prognosis in patients with advanced stage sex cord-stromal tumors. Poster presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) Sep 2018.

Nasioudis D; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Ko EM; Latif NA.: Does surgical approach influence the rate of positive peritoneal cytology and lymph-vascular invasion for patients with stage I uterine cancer. Poster presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) Sep 2018.

Nasioudis D; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Ko EM; Latif NA.: Is adjuvant chemotherapy associated with a survival benefit for patients with stage I mucinous ovarian carcinoma?” Oral presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) Sep 2018.

Nasioudis D; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Ko EM; Latif NA.: Minimally invasive staging for stage I type II uterine cancer: use and outcomes. Poster presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) Sep 2018.

Nasioudis D; Mastroyannis SA; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Ko EM; Latif NA.: Presence of lymph-vascular invasion is associated with a worse prognosis for patients with advanced stage malignant ovarian germ cell tumors. Poster presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) Sep 2018.

Burger RA, Deng W, Makker V, Collins Y, Gray H Debernardo R, Martin LP, Aghajanian C.: Phase II Evaluation of Dalantercept in the Treatment of Persistent or Recurrent Epithelial Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group Study Gynecol Oncol 150(3): 466-470, Sep 2018.

back to top
Last updated: 02/09/2019
The Trustees of the University of Pennsylvania